BioNTech has commissioned Dermapharm Holding with the production of a COVID-19 vaccine within the framework of a newly concluded cooperation and supply agreement. “If the vaccine is approved, the Dermapharm Group will provide and expand production capacities at the German site in order to be able to offer BioNTech the greatest possible support,” Dermapharm reported on Thursday, September 10th. The company from Grünwald did not present financial details of the agreements.
“Dermapharm has special know-how in the manufacture of aseptic products and in the handling of lipids, to which a key function is attributed in the formulation of vaccines,” said Hans-Georg Feldmeier, CEO of Dermapharm Holding SE. The necessary prerequisites have been created in the production facility in a very short time.
Find out when the vaccine against COVID-19 developed by BioNTech and Pfizer will be ready to use and read the latest business news with the Born2Invest mobile app.
BioNTech’s COVID-19 vaccine candidate is currently undergoing final clinical testing
Together with its cooperation partner Pfizer, the Mainz-based biotech company intends to apply for approval in October, at the latest at the beginning of November. BioNTech and Pfizer have announced that they intend to produce around 100 million doses of the vaccine by 2020 and are already building up capacities for this purpose; by 2021, this figure is expected to be 1.3 billion doses. One of the customers for BioNTech’s COVID-19 vaccine will be the EU.
Dermapharm’s share price reacted to the news in the afternoon with a jump in price. While the share was previously quoted at $51 (€43.1), the share price has jumped to $55.5 (€46.8)in the course of trading to date. There is hardly any movement for BioNTech’s shares on the US pre-market; the indications currently oscillate around yesterday’s (September 9th) NASDAQ closing price of the biotech share.
Despite the problems with AstraZeneca’s corona vaccine project, the BioNTech share price recorded a noticeable gain yesterday. The company’s own vaccine project is making good progress and already next month or at the beginning of November, the Mainz-based company could submit an application for approval together with its research partner Pfizer. In addition, there was news yesterday: The EU has secured up to 300 million vaccine doses from BioNTech and Pfizer against the COVID-19 pathogen, the SARS-CoV-2 virus.
However, from a chartist point of view, the rise in BioNTech’s share price on September 9th did not bring any decisive bullish impulses. Intraday the share price rose to $63.38 before trading ended on the NASDAQ at $62.32. The Biotech stock thus overcame a first minor technical hurdle of $59.96/60.34 and the daily high of $61.00 on Tuesday, September 8th. However, BioNTech’s share price missed major buy signals at the stronger obstacles in the zone between 63.67/64.08 and the $65.50/66.12 range. Instead, the stock bounced down at the lower end of the signal zone.
However, the chart technical hurdles for the BioNTech stock are still within reach and breakout attempts are still possible. And so the technical chart conclusion remains unchanged. If there would be buy signals at the zone between $63.67/$64.08 and the area around $65.5/$66.12, clear impulses for an upward turnaround would be present, after the BioNTech stock had fallen significantly recently. Without these buy signals, however, the risks of falling share prices in view of the intact short-term downtrend would still remain with the Biotech share. Thus, the support zone at $54.10/$54.96 remains the first and possibly decisive technical signal mark on the underside for the Mainz share.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in 4investors, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Gaming Startups: winning is about more than racking up a high score
It is news to no one that the gaming industry has exploded into the entertainment sector, and beyond it. Yet...
RheoDx is looking for one million euros to accelerate blood diagnostics
The Spanish startup has received $800,000 (€669,000) from the Center for the Development of Industrial Technology and will seek an...
Consumer Price Index in Spain confirms its positive path and rises 1.3% in March
In monthly rate (March over February), the CPI jumped 1%, its highest monthly rebound since October 2019, driven by the...
The Moroccan tourism sector might take a breath of fresh air
The Moroccan Ministry of Transport is willing to develop a contract-program for tourist transport, in order to respond to repeated...
Aedas Homes hires Goldman Sachs to launch green bond issue
The operation of Aedas Homes will be the third of this type that is carried out in the promoter sector...
Biotech7 days ago
Aortyx closes €1.6 million financing round to initiate clinical trials
Cannabis6 days ago
Canopy Growth bought out its competition to consolidate leadership
Crypto7 days ago
US crypto exchange Coinbase had a record quarter before IPO
Crowdfunding7 days ago
Third successful million-dollar campaign in three months for Walliance